<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02007811</url>
  </required_header>
  <id_info>
    <org_study_id>UKER-BLZ-PH1</org_study_id>
    <nct_id>NCT02007811</nct_id>
  </id_info>
  <brief_title>Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination</brief_title>
  <acronym>B-cell therapy</acronym>
  <official_title>Prospective, Open-label, Multicentre Clinical Trial, Phase I/IIa, to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates CD3+-Depleted, CD19+-Enriched, Cryopreserved (Single Administration After Day 120 Following Allogeneic Stem Cell Transplantation (SCT), Donor-identical) in 4 Groups With Escalating Doses for Immune Response Enhancement, Measured as Response to a Antedated Single Vaccination</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Erlangen-Nürnberg Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital Regensburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuerzburg University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Essen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>German Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Erlangen-Nürnberg Medical School</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The reconstitution of a functioning immune system after allogeneic stem cell transplantation
      takes months to years. Particularly memory B-lymphocytes reconstitute poorly with the current
      conditioning regimes. During the period of intense immune suppression the patients are
      extremely susceptible to bacterial, fungal and, most importantly, viral infections.The
      adoptive transfer of B-lymphocytes from the stem-cell donor might significantly enhance
      humoral immunity for the patient. Aim of the study is to evaluate a new cellular therapy with
      B-lymphocytes regarding safety. A booster vaccination after B-lymphocyte transfer will
      evaluate the functionality of the transferred B-lymphocytes in the patient.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with EBV DNA copies/ml plasma higher than 50,000</measure>
    <time_frame>for 120 days after administration of study medication</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with signs of a post-transplant lymphoproliferative disorder (PTLD)</measure>
    <time_frame>for 120 days after administration of study medication</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with adverse events (AEs), adverse reactions (ARs), serious adverse events (SAEs), serious adverse reactions (SARs) and suspected unexpected serious adverse reaction (SUSARs)</measure>
    <time_frame>for 120 days after administration of study medication</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the frequency of antibody-producing cells between dose groups</measure>
    <time_frame>before and 7 days after preponed single vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of mean absolute number of B-lymphocytes, naïve B-lymphocytes and memory B-lymphocytes between dose groups.</measure>
    <time_frame>1 day before and up to 120 days after administration of study medication</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of antigen-specific antibody concentration in serum/plasma between dose groups</measure>
    <time_frame>1 day before and up to 120 days after administration of study medication</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Cytomegalovirus (CMV) DNA copies/ml plasma between dose groups</measure>
    <time_frame>1 day before and up to 120 days after administration of study medication</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with &gt;5,000 CMV DNA copies/ml plasma or with signs of organ infestation by CMV between dose groups.</measure>
    <time_frame>up to 120 days after administration of study medication</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Chronic Myeloid Leukemia</condition>
  <condition>Non Hodgkin's Lymphoma</condition>
  <condition>Hodgkin's Disease</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Aplastic Anemia</condition>
  <arm_group>
    <arm_group_label>allogeneic donor derived B-lymphocytes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>allogeneic donor derived B-lymphocytes</intervention_name>
    <description>CD3+-depleted, CD19+-enriched, cryopreserved (single administration after day 120 following allogeneic stem cell transplantation, donor-identical) in 4 groups with escalating doses</description>
    <arm_group_label>allogeneic donor derived B-lymphocytes</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. patients after allogeneic stem cell transplantation

          2. Serostatus for EBV: R-/D- oder R+/D- oder R+/D+

        Exclusion Criteria:

          1. Serostatus for EBV: R-/D+

          2. Severe acute Graft versus Host Disease (GvHD) (Glucksberg grade III und IV)

          3. Chronic GvHD in middle- or high-risk group according to NIH staging

          4. Rituximab administration after SCT

          5. &gt;10.000 EBV DNA copies/ml plasma

          6. Recurrence of the haematological disorder needing therapeutic intervention

          7. Secondary transplantation

          8. SCT with transplant from a haploidentical donor

          9. SCT with transplant from umbilical cord blood

         10. CD34+-enriched transplant

         11. in vitro T-cell depleted transplant

         12. Pregnant or breast-feeding female
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julia Winkler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Erlangen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julia Winkler, MD</last_name>
    <phone>+49 9131 85 43112</phone>
    <email>julia.winkler@uk-erlangen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wolf Rösler, MD</last_name>
    <phone>+49 9131 85 43115</phone>
    <email>wolf.roesler@uk-erlangen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical Department 5, University Hospital Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Winkler, MD</last_name>
      <phone>+49 9131 85 43112</phone>
      <email>julia.winkler@uk-erlangen.de</email>
    </contact>
    <contact_backup>
      <last_name>Andreas Mackensen, MD</last_name>
      <phone>+49 9131 85 35954</phone>
      <email>andreas.mackensen@uk-erlangen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Julia Winkler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2013</study_first_submitted>
  <study_first_submitted_qc>December 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2013</study_first_posted>
  <last_update_submitted>March 24, 2014</last_update_submitted>
  <last_update_submitted_qc>March 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

